Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 12, 2024

BUY
$12.46 - $29.95 $142,293 - $342,029
11,420 New
11,420 $338,000
Q4 2018

Jan 22, 2019

SELL
$3.94 - $9.7 $1,576 - $3,879
-400 Closed
0 $0
Q2 2018

Jul 18, 2018

BUY
$9.52 - $12.15 $3,808 - $4,860
400 New
400 $3,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Fny Investment Advisers, LLC Portfolio

Follow Fny Investment Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fny Investment Advisers, LLC with notifications on news.